ABSTRACT
Introduction Peri-prosthetic Joint Infection (PJI) after total knee arthroplasty (TKA) is a devastating complication. Intra-wound vancomycin powder has been shown to reduce infection rates in spine surgery. Previous studies on the efficacy of local vancomycin powder in hip or knee arthroplasty are mostly retrospective case series. The aim of this prospective RCT was to evaluate the efficacy and safety of intrawound vancomycin in preventing PJI after primary TKA.
Methods This study was a National Trial Registry-approved RCT of patients undergoing primary TKA. 1022 patients were randomized to the study group (n=507, received 2g intrawound vancomycin powder before arthrotomy closure) and control groups (n=515, no local vancomycin). The minimum follow-up was 12-months. The primary outcome was PJI rate. Secondary outcomes included surgical site infection (SSI) rates, incidence of revision for PJI/SSI, and incidence of wound complications. High-risk groups (Obesity and Diabetes) in both cohorts were also evaluated.
Results The overall infection rate in 1022 patients was 0.66%. There was no significant difference in PJI rate in the study group (0.2%) versus the control group (0.58%), p=0.264. Reoperation rates in the study group (N=4;0.78%) and Control (N=5;0.97%) and SSI rates in the study (N=1;0.2%) and control groups (N=2;0.38%) were comparable. The Vancomycin cohort however demonstrated a significantly higher number of minor wound complications (n=67;13.9%) compared to the control group (n=39;8.4%, p<0.05). There was no difference in PJI/SSI rates or minor surgical complications among high-risk groups and no cases of nephrotoxicity were reported in the study.
Conclusion Intra-wound vancomycin powder does not appear to reduce PJI/SSI rate in primary total knee arthroplasties, including high-risk groups. Although safe from a renal perspective, intra-wound vancomycin was associated with an increase in postoperative aseptic wound complications such as persistent wound drainage. Intra-wound vancomycin may not be effective in reducing the rate of PJI in primary TKA.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Central Trial Registry of India (CTRI/2021/02/031310)
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee/IRB of Sunshine Bone and Joint Institute gave ethical approval for this work. This trial was prospectively registered with the Central Trial Registry of India (CTRI/2021/02/031310)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Praharshamulpur9{at}gmail.com
yakkanti1{at}gmail.com
dradityaapte{at}gmail.com
kushalhippal{at}gmail.com
dr.adarshannapareddy{at}gmail.com
drsuhas09{at}gmail.com
guravareddy{at}gmail.com
Data Availability
All data produced in the present study are available upon reasonable request to the authors